About this trial
SCINC is an adaptive design Master protocol that seeks to determine if there is "sufficient promise" of beneficial effect of treatment combinations to enhance motor recovery in pre-specified strata of people with a spinal cord injury.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Adults > 18 years of age
Able to independently ventilate
Chronic SCI (>1 years post-injury or impairment onset)
Tetraplegia (C2-T1 level of injury)
Trial design
Single group
Treatments tested in this trial
Therapeutic Intermittent Hypoxia (TIH) + Exercise Training (ET)
Other interventionTIH in combination with upper limb and respiratory ET. The intervention is predominantly home-based and will be delivered three times per week for six weeks.
Treatment groups
Trial outcomes
Primary outcomes
At an individual participant level, the Phase IIA study has a single, binary, composite primary outcome to determine if there is a 'signal of benefit', measuring effectiveness, no deterioration, safety and acceptability.
The single binary outcome includes the following components: A) Effectiveness - Increase above baseline that is equal or more than the predefined outcome-specific stated thresholds, on at least ONE of the: Action Reach Arm Test (ARAT), Handheld dynamometer (GRIP) Maximal inspiratory pressure (MIP) B) No deterioration - No deterioration below baseline. C) Safety - Incidence of Autonomic Dysreflexia (AD) episodes occurring during the intervention period for each individual participant. D) Acceptability - Rate of participant adherence to intervention sessions. Please refer to the following primary outcomes for details of each of these components.
A) Effectiveness: Increase above baseline that is equal or more than the predefined outcome-specific stated thresholds, on at least ONE of the: Action Reach Arm Test (ARAT), Handheld dynamometer (GRIP) Maximal inspiratory pressure (MIP)
ARAT: Assesses grasp, grip, pinch and gross movement. A minimal clinically important difference of 5.7 points is accepted in SCI. GRIP: Grip strength will be measured according to a standardised procedure. A threshold of 5.0 kg will be used. MIP: Respiratory muscle strength will be measured according to standard procedures. A threshold of 10cmH20 will be used.
B) No deterioration
No deterioration (decline below baseline) that is equal or more than the predefined outcome-specific stated threshold, on ANY of the ARAT, GRIP and MIP.
C) Safety - Incidence of Autonomic Dysreflexia (AD) episodes occurring during the intervention period for each individual participant.
Fewer than two AD events that fail to resolve with participants usual, community interventions.
Secondary outcomes
9-hole Peg test
A test of upper limb dexterity and function. This test will be undertaken using the dominant hand.
Pinch grip dynamometer
Pinch strength
Penn Spasm Frequency Scale
Self-report measure of upper limb spasticity composed of 2-parts: 1. Spasm frequency: scale 0 (no spasm) - 4 (spasms occurring more than 10 times per hour). 2. Spasm severity: scale 1 (mild) - 3 (severe). A higher score indicates a worse outcome for both components of the scale.
Capabilities of upper extremity questionnaire
Questionnaire assessing upper limb function. Scored on a 7-point scale representing self-perceived difficulty: 1= "totally limited, can't do at all" 7= "not at all limited" Minimum score = 32 Maximum score = 224 (higher score = greater function)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Melbourne
Lead sponsor
Institute of Breathing and Sleep
Collaborator
Austin Health
Collaborator
Neuroscience Research Australia
Collaborator
The University of New South Wales
Collaborator
University of Sydney
Collaborator
University of Florida
Collaborator